Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Amphetamine

or Anticonvulsant

or Benzodiazepine

Use the filters below to narrow your results.

None (15) · Adderall, Adderall XR, Mydayis (1) · Aptiom (1) · Banzel (1) · Briviact (1) · Captagon (1) · Cerebyx (1) · Dalmane (1) · Depakote (1) · Desoxyn (1) · Dexedrine (1) · Diacomit (1) · Dilantin (1) · Doral (1) · Epidiolex (1) · Felbatol (1) · Fintepla (1) · Fycompa (1) · Gabitril (1) · Halcion (1) · Lexotan (1) · Librium (1) · Luminal (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Sabril (1) · Serax (1) · Tranxene (1) · Versed (1) · Vimpat (1) · Xanax (1) · Xcopri (1) · Zarontin (1) · Zonegran (1)

AMPA receptor antagonist (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Monoamine releasing agent (6) · Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Prodrug of amphetamine + theophylline (1) · Prodrug of phenytoin; sodium channel blocker (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1) · TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport, net release of dopamine and norepinephrine (1)

None (48) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) · '"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"' (1) · '"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"' (1)

None (48) · 0.25 mg (1) · 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis (1) · 5 mg PO (1)

None (48) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · Desoxyn 5 mg tabs (1) · IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1)

None (48) · 10 mg/d (1) · 25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label) (1) · XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"' (1)

None (48) · Oral (2) · Oral (prescribed) (1)

None (49) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · IR: 30–60 min; XR: 1–2 h to peak effect (1)

None (49) · 6 h (immediate-release); ~11 h (extended-release) (1) · IR 4–6 h; XR 10–12 h; Mydayis 14–16 h (1)

None (49) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · D-amphetamine ~10 h; L-amphetamine ~13 h (adults) (1)

None (49) · 80-90% oral (1) · ~75–90% (oral) (1)

None (48) · Category C (1) · Category C (per Desoxyn label) (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1)